Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation

Academic Article

Abstract

  • A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. The patient was successfully treated with bortezomib, a proteasome inhibitor, and has remained well as an outpatient without evidence of ongoing haemolysis.
  • Authors

    Published In

  • BMJ Case Reports  Journal
  • Digital Object Identifier (doi)

    Pubmed Id

  • 19710014
  • Author List

  • Wong D; Thomas W; Butler A; Sharkey L
  • Volume

  • 14
  • Issue

  • 5